![](/sites/default/files/styles/vertical_teaser/public/2019-02/CIMZIA_FAB.png?itok=-kngiJOp)
![](/sites/default/files/styles/vertical_teaser/public/2019-07/rheumatology_info_brochure_resized_v2.jpg?itok=jry3tulf)
![](/sites/default/files/styles/vertical_teaser/public/2019-07/cf5fb56dbbac54f0007266462599aee5-resized.jpg?itok=NqFrXI9O)
![](/sites/default/files/styles/vertical_teaser/public/2019-01/monograph-small.png?itok=0Gljq4Uc)
![](/sites/default/files/styles/vertical_teaser/public/2019-01/syringe-e-390x230.png?itok=AmFN2ZT5)
![](/sites/default/files/styles/vertical_teaser/public/2019-02/Cimzia_logo_very_small.png?itok=iiltGifz)
![](/sites/default/files/styles/vertical_teaser/public/2019-01/5th-300x168.jpg?itok=ax1zo3sW)
PrCIMZIA® (certolizumab pegol) in combination with methotreaxate (MTX) is indicated for:
PrCIMZIA® may be used alone for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis (RA) who do not tolerate MTX.
PrCIMZIA® alone or in combination with methotrexate (MTX) is indicated for:
PrCIMZIA® is indicated for:
PrCIMZIA® is indicated for:
If you have any question, please contact the: UCBCares™ call-centre at 1-800-908-5555.
The call centre is available from 8am to 8pm. Nurse case managers are available from 9am to 5pm EST.